tiprankstipranks
Jounce Therapeutics (JNCE)
NASDAQ:JNCE
Holding JNCE?
Track your performance easily

Jounce Therapeutics (JNCE) Income Statement

0 Followers

Jounce Therapeutics Income Statement

Last quarter (Q ), Jounce Therapeutics's total revenue was $82.00M, an increase of Infinity% from the same quarter last year. In Q, Jounce Therapeutics's net income was $50.96M. See Jounce Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 82.00M$ 82.00M$ 26.91M$ 62.34M$ 147.87M$ 65.20M
Cost of Revenue
------
Gross Profit
$ 82.00M$ 82.00M----
Operating Expense
$ 70.92M$ -134.24M$ 117.96M$ 107.46M$ 95.06M$ 96.50M
Operating Income
$ -52.24M$ -52.24M$ -91.06M$ -45.12M$ 52.82M$ -31.29M
Net Non Operating Interest Income Expense
------
Other Income Expense
$ -16.00K$ -1.46M$ 199.00K$ 1.29M$ 4.05M$ 3.96M
Pretax Income
$ -50.78M$ -50.78M$ -90.86M$ -43.83M$ 56.87M$ -27.33M
Tax Provision
$ 135.00K$ 135.00K$ 15.00K$ 14.00K$ 46.00K$ 46.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -50.92M$ -50.92M$ -90.87M$ -43.84M$ 56.82M$ -27.38M
Basic EPS
$ -0.99$ -0.99$ -1.82$ -1.24$ 1.72$ -0.84
Diluted EPS
$ -0.99$ -0.99$ -1.82$ -1.24$ 1.66$ -0.84
Basic Average Shares
$ 206.69M$ 51.68M$ 49.93M$ 35.43M$ 33.08M$ 32.57M
Diluted Average Shares
$ 206.69M$ 51.68M$ 49.93M$ 35.43M$ 34.29M$ 32.57M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 70.92M$ -134.24M$ 117.96M$ 107.46M$ 95.06M$ 96.50M
Net Income From Continuing And Discontinued Operation
$ -50.92M$ -50.92M$ -90.87M$ -43.84M$ 56.82M$ -27.38M
Normalized Income
$ -101.88M-$ -90.87M$ -43.84M$ 56.82M$ -27.38M
Interest Expense
------
EBIT
$ -51.51M$ -50.78M$ -91.06M$ -45.12M$ 52.82M$ -31.29M
EBITDA
$ -49.26M$ -47.79M$ -88.23M$ -41.72M$ 56.67M$ -27.46M
Currency in USD

Jounce Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis